Showcases Stock ranks Forex

Heron Therapeutics (HRTX)
3.57  0.35 (10.87%) 08-08 16:00
Open: 3.33 Pre. Close: 3.22
High: 3.8 Low: 3.3
Volume: 4,565,380 Market Cap: 366M
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 3.805 - 3.819 3.819 - 3.83
Low: 3.266 - 3.282 3.282 - 3.295
Close: 3.545 - 3.571 3.571 - 3.592
Stock Technical Analysis
Target: Six months: 4.44
One year: 5.18
Support: Support1: 3.05
Support2: 2.58
Resistance: Resistance1: 3.80
Resistance2: 4.44
Pivot: 2.94
Moving Averages: MA(5): 3.09
MA(20): 2.95
MA(100): 3.86
MA(250): 7.30
MACD: MACD(12,26): 0.02
Signal(12,26,9): -0.05
%K %D: %K(14,3): 70.34
%D(3): 56.64
RSI: RSI(14): 66.66
52-Week: High: 12.89
Low: 2.19
Change(%): -66.4
Average Vol(K): 3-Month: 2710
10-Days: 2717
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ HRTX ] has closed above the upper band by 17.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Mon, 08 Aug 2022
Heron Therapeutics Q2 2022 Earnings Preview (NASDAQ:HRTX) - Seeking Alpha

Tue, 26 Jul 2022
Nisa Investment Advisors LLC Has $328000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Mon, 18 Jul 2022
7 Biotech Stocks to Buy for Q3 - Nasdaq

Thu, 30 Jun 2022
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability - Yahoo Finance

Tue, 14 Jun 2022
2022-06-14 | NDAQ:HRTX | Press Release | Heron Therapeutics Inc. - Stockhouse

Mon, 16 May 2022
Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting - Yahoo Finance

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 102.48
Shares Float (M) 77.56
% Held by Insiders 0.24
% Held by Institutions 119.05
Shares Short (K) 40180
Shares Short Prior Month (K) 38980
Stock Financials
EPS -2.293
Book Value (p.s.) 0.230
Profit Margin -258.35
Operating Margin -254.65
Return on Assets (ttm) -48.9
Return on Equity (ttm) -210.7
Qtrly Rev. Growth 17.2
Gross Profit (p.s.) -0.883
Sales Per Share 0.876
EBITDA (p.s.) -2.202
Qtrly Earnings Growth
Operating Cash Flow (M) -205.36
Levered Free Cash Flow (M) -102.33
Stock Valuation
PE Ratio -1.56
PEG Ratio -0.03
Price to Book value 15.52
Price to Sales 4.07
Price to Cash Flow -1.78
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android